Men's mutagenomic applications and advances in malignancies treatment: a narrative review

Cancer has higher incidence and mortality rates in men compared to women because of the sex genetics. Tumors and malignant diseases such as gallbladder, pancreas and liver cancers have poor prognosis which threaten the human lives. Conducive treatment strategies are thus required to improve men’s health. Herein, phenotypic screening of strains, bacteria and microbiomes by the mutational genomics is presented as novel therapeutic strategy. Mutant genomes can reduce toxicity, negative stress and sensitivity of the human body through genomic resetting and recombination. However, studies are lacking on microbial or genome-related therapeutics from the pharmacological perspective. This paper thus presents new strategies and directions in anticancer therapy including mutant genome-based human epidermal growth factor receptor 2 (HER2)/neu, vascular endothelial growth factor/vascular endothelial growth factor receptor (VEGF/VEGFR), mitogen-activated protein kinase (MAPK) rat sarcoma/rapidly accelerated fibrosarcoma/MAPK/ERK Kinase/extracellular signal-regulated kinase (RAS/RAF/MEK/ERK) pathway, phosphoinositide 3-Kinase/protein kinase B/mammalian target of rapamycin (PI3K/AKT/mTOR) pathway, programmed death-1/programmed death-ligand 1 (PD-1/PD-L1), high tumor mutational burden (TMB) and immune checkpoint inhibitor (ICI) therapy. They are all relevant to human physiology. Moreover, strategies for treating aggressive tumors and preventive cancer are discussed along with the clinical case studies for future therapeutic applications.

Mutagenomic; Malignancies; HER2/neu; VEGR; Men’s health

[1] Wang S, Zheng R, Li J, Zeng H, Li L, Chen R, et al. Global, regional, and national lifetime risks of developing and dying from gastrointestinal cancers in 185 countries: a population-based systematic analysis of GLOBOCAN. The Lancet Gastroenterology & Hepatology. 2024; 9: 229–237.

[2] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA: A Cancer Journal for Clinicians. 2016; 66: 7–30.

[3] GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016. The Lancet. 2017; 390: 1151–1210.

[4] Islam MM, Iqbal U, Walther BA, Nguyen P, Li Y, Dubey NK, et al. Gender-based personalized pharmacotherapy: a systematic review. Archives of Gynecology and Obstetrics. 2017; 295: 1305–1317.

[5] Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017; 66: 683–691.

[6] Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Allen C, Barber RM, Barregard L, Bhutta ZA, Brenner H, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncology. 2017; 3: 524–548.

[7] Zucker I, Beery AK. Males still dominate animal studies. Nature. 2010; 465: 690.

[8] Kim H, Lim H, Moon A. Sex differences in cancer: epidemiology, genetics and therapy. Biomolecules & Therapeutics. 2018; 26: 335–342.

[9] Chiu CY, Miller SA. Clinical metagenomics. Nature Reviews Genetics. 2019; 20: 341–355.

[10] Talukdar D, Sinjushin A. Cytogenomics and mutagenomics in plant functional biology and breeding. In Barh D, Khan MS, Davies E (eds.) PlantOmics: the omics of plant science (pp. 113–156). 1st edn. Springer: New Delhi. 2015.

[11] Chen S, Chuang Y, Lin T, Yang J. Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases. European Journal of Pharmacology. 2023; 938: 175439.

[12] Blyth HR, Smith D, King R, Bayon C, Ashfield T, Walpole H, et al. Fungal plant pathogen “mutagenomics” reveals tagged and untagged mutations in Zymoseptoria tritici and identifies SSK2 as key morphogenesis and stress-responsive virulence factor. Frontiers in Plant Science. 2023; 14: 1140824.

[13] Haiser HJ, Turnbaugh PJ. Developing a metagenomic view of xenobiotic metabolism. Pharmacological Research. 2013; 69: 21–31.

[14] Zhou BP, Hung MC. Dysregulation of cellular signaling by HER2/neu in breast cancer. Seminars in Oncology. 2003; 30: 38–48.

[15] Lohrisch C, Piccart M. Her2/neu as a predictive factor in breast cancer. Clinical Breast Cancer. 2001; 2: 129–135.

[16] Chen J, Lan K, Hung M. Strategies to target HER2/neu overexpression for cancer therapy. Drug Resistance Updates. 2003; 6: 129–136.

[17] Jayraj AS, Abdul-Aziz S, Mburu A, Upadhyay A, Singh N, Ghatage P. Narrative review on the evolving role of HER2/neu targeting in uterine serous cancers. To be published in Annals of Translational Medicine. 2023. [Preprint].

[18] Ellis LM, Hicklin DJ. VEGF-targeted therapy: mechanisms of anti-tumour activity. Nature Reviews Cancer. 2008; 8: 579–591.

[19] Xu D, Li J, Jiang F, Cai K, Ren G. The effect and mechanism of vascular endothelial growth factor (VEGF) on tumor angiogenesis in gallbladder carcinoma. Iranian Journal of Public Health. 2019; 48: 713–721.

[20] Yang X, Zhang Y, Hosaka K, Andersson P, Wang J, Tholander F, et al. VEGF-B promotes cancer metastasis through a VEGF-A—independent mechanism and serves as a marker of poor prognosis for cancer patients. Proceedings of the National Academy of Sciences. 2015; 112: E2900–E2909.

[21] Li Z, Li C, Bao R, Liu Z. Expressions of miR-29a, TNF-Α and vascular endothelial growth factor in peripheral blood of pulmonary tuberculosis patients and their clinical significance. Iranian Journal of Public Health. 2020; 49: 1683–1691.

[22] Mousa AM, El-Sammad NM, Abdel-Halim AH, Anwar N, Khalil WKB, Nawwar M, et al. Lagerstroemia speciosa (L.) pers leaf extract attenuates lung tumorigenesis via alleviating oxidative stress, inflammation and apoptosis. Biomolecules. 2019; 9: 871.

[23] Saikia Q, Reeve H, Alzahrani A, Critchley WR, Zeqiraj E, Divan A, et al. VEGFR endocytosis: implications for angiogenesis. Progress in Molecular Biology and Translational Science. 2023; 53: 109–139.

[24] Miao FR, Zhang P, Zhao CJ. Effect of Herbal-cake-separated moxibustion on macrophage phagocytosis and activation of VEGF/VEGFR pathway in endometriosis rats. Acupuncture Research. 2022; 47: 115–120. (In Chinese)

[25] Yue J, López JM. Understanding MAPK signaling pathways in apoptosis. International Journal of Molecular Sciences. 2020; 21: 2346.

[26] Moens U, Kostenko S, Sveinbjørnsson B. The role of mitogen-activated protein kinase-activated protein kinases (MAPKAPKs) in inflammation. Genes. 2013; 4: 101–133.

[27] Guo YJ, Pan WW, Liu SB, Shen ZF, Xu Y, Hu LL. ERK/MAPK signalling pathway and tumorigenesis. Experimental and Therapeutic Medicine. 2020; 19: 1997–2007.

[28] Santarpia L, Lippman SM, El-Naggar AK. Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy. Expert Opinion on Therapeutic Targets. 2012; 16: 103–119.

[29] Quan Z, Yang Y, Zheng H, Zhan Y, Luo J, Ning Y, et al. Clinical implications of the interaction between PD-1/PD-L1 and PI3K/AKT/mTOR pathway in progression and treatment of non-small cell lung cancer. Journal of Cancer. 2022; 13: 3434–3443.

[30] Zhang M, Wang L, Liu W, Wang T, De Sanctis F, Zhu L, et al. Targeting inhibition of accumulation and function of myeloid-derived suppressor cells by artemisinin via PI3K/AKT, mTOR, and MAPK pathways enhances anti-PD-L1 immunotherapy in melanoma and liver tumors. Journal of Immunology Research. 2022; 2022: 2253436.

[31] Lu Y, Zhong W, Liu Y, chen W, zhang J, Zeng Z, et al. Anti-PD-L1 antibody alleviates pulmonary fibrosis by inducing autophagy via inhibition of the PI3K/Akt/mTOR pathway. International Immunopharmacology. 2022; 104: 108504.

[32] Castle JC, Uduman M, Pabla S, Stein RB, Buell JS. Mutation-derived neoantigens for cancer immunotherapy. Frontiers in Immunology. 2019; 10: 1856.

[33] Schumacher TN, Scheper W, Kvistborg P. Cancer neoantigens. Annual Review of Immunology. 2019; 37: 173–200.

[34] Ahmed J, Das B, Shin S, Chen A. Challenges and future directions in the management of tumor mutational burden-high (TMB-H) advanced solid malignancies. Cancers. 2023; 15: 5841.

[35] Jung J, Heo YJ, Park S. High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis. Journal for ImmunoTherapy of Cancer. 2023; 11: e006454.

[36] Qian Z, Pan Y, Li X, Chen Y, Wu H, Liu Z, et al. Modulator of TMB-associated immune infiltration (MOTIF) predicts immunotherapy response and guides combination therapy. Science Bulletin. 2024; 69: 803–822.

[37] Roque K, Ruiz R, Mas L, Pozza DH, Vancini M, Silva Júnior JA, de Mello RA. Update in immunotherapy for advanced non-small cell lung cancer: optimizing treatment sequencing and identifying the best choices. Cancers. 2023; 15: 4547.

[38] Aggarwal C, Ben-Shachar R, Gao Y, Hyun SW, Rivers Z, Epstein C, et al. Assessment of tumor mutational burden and outcomes in patients with diverse advanced cancers treated with immunotherapy. JAMA Network Open. 2023; 6: e2311181.

[39] Vryza P, Fischer T, Mistakidi E, Zaravinos A. Tumor mutation burden in the prognosis and response of lung cancer patients to immune-checkpoint inhibition therapies. Translational Oncology. 2023; 38: 101788.

[40] Florou V, Floudas CS, Maoz A, Naqash AR, Norton C, Tan AC, et al. Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden. Journal for ImmunoTherapy of Cancer. 2023; 11: e007440.

[41] Wu H, Wang H, Chen Y. Pan-cancer analysis of tumor mutation burden sensitive tumors reveals tumor-specific subtypes and hub genes related to immune infiltration. Journal of Cancer Research and Clinical Oncology. 2023; 149: 2793–2804.

[42] Moretton A, Loizou JI. Interplay between cellular metabolism and the DNA damage response in cancer. Cancers. 2020; 12: 2051.

[43] Qing T, Jun T, Lindblad KE, Lujambio A, Marczyk M, Pusztai L, et al. Diverse immune response of DNA damage repair-deficient tumors. Cell Reports Medicine. 2021; 2: 100276.

[44] Jiang M, Jia K, Wang L, Li W, Chen B, Liu Y, et al. Alterations of DNA damage repair in cancer: from mechanisms to applications. Annals of Translational Medicine. 2020; 8: 1685–1685.

[45] Bret C, Klein B, Moreaux J. Nucleotide excision DNA repair pathway as a therapeutic target in patients with high-risk diffuse large B cell lymphoma. Cell Cycle. 2013; 12: 1811–1812.

[46] Lieber MR. The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway. Annual Review of Biochemistry. 2010; 79: 181–211.

[47] Kerzendorfer C, O’Driscoll M. Human DNA damage response and repair deficiency syndromes: Linking genomic instability and cell cycle checkpoint proficiency. DNA Repair. 2009; 8: 1139–1152.

[48] Huang R, Zhou PK. DNA damage repair: historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduction and Targeted Therapy. 2021; 6: 254.

[49] Burdak-Rothkamm S, Mansour WY, Rothkamm K. DNA damage repair deficiency in prostate cancer. Trends in Cancer. 2020; 6: 974–984.

[50] Choi E, Buie J, Camacho J, Sharma P, de Riese WTW. Evolution of androgen deprivation therapy (ADT) and its new emerging modalities in prostate cancer: an update for practicing urologists, clinicians and medical providers. Research and Reports in Urology. 2022; 14: 87–108.

[51] Wang R, Min Q, Guo Y, Zhou Y, Zhang X, Wang D, et al. GL-V9 inhibits the activation of AR-AKT-HK2 signaling networks and induces prostate cancer cell apoptosis through mitochondria-mediated mechanism. iScience. 2024; 27: 109246.

[52] Whetton AD, Preston GW, Abubeker S, Geifman N. Proteomics and informatics for understanding phases and identifying biomarkers in COVID-19 disease. Journal of Proteome Research. 2020; 19: 4219–4232.

[53] Danesh Pazhooh R, Rahnamay Farnood P, Asemi Z, Mirsafaei L, Yousefi B, Mirzaei H. MTOR pathway and DNA damage response: a therapeutic strategy in cancer therapy. DNA Repair. 2021; 104: 103142.

[54] De Vitto H, Arachchige DB, Richardson BC, French JB. The intersection of purine and mitochondrial metabolism in cancer. Cells. 2021; 10: 2603.

[55] Charles C, Lloyd SM, Piyarathna DWB, Gohlke J, Rasaily U, Putluri V, et al. Role of adenosine deaminase in prostate cancer progression. American Journal of Clinical and Experimental Urology. 2023; 11: 594–612.

[56] Janiszewska M, Primi MC, Izard T. Cell adhesion in cancer: beyond the migration of single cells. Journal of Biological Chemistry. 2020; 295: 2495–2505.

[57] Rakké YS, Buschow SI, IJzermans JNM, Sprengers D. Engaging stimulatory immune checkpoint interactions in the tumour immune microenvironment of primary liver cancers—how to push the gas after having released the brake. Frontiers in Immunology. 2024; 15: 1357333.

[58] Bavaro DF, Diella L, Pizzutilo P, Catino A, Signorile F, Pesola F, et al. Incidence and predictors of infections in patients with advanced non-small cell lung cancer treated with checkpoint inhibitor immunotherapies: a monocentric retrospective cohort study. Scandinavian Journal of Immunology. 2023; 98: e13303.

[59] Zhao T, Wei P, Zhang C, Zhou S, Liang L, Guo S, et al. Nifuroxazide suppresses PD-L1 expression and enhances the efficacy of radiotherapy in hepatocellular carcinoma. eLife. 2024; 12: RP90911.

[60] Pang S, Zhao S, Dongye Y, Fan Y, Liu J. Identification and validation of m6A-associated ferroptosis genes in renal clear cell carcinoma. Cell Biology International. 2024; 48: 777–794.